An Integrated Safety Profile Analysis of Belatacept in Kidney Transplant Recipients-Reference-Cited by-同舟云学术

An Integrated Safety Profile Analysis of Belatacept in Kidney Transplant Recipients

Published:2010-12-27 Issue:12 Volume:90 Page:1521-1527
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:

Author:

Grinyó Josep,Charpentier Bernard,Pestana José Medina,Vanrenterghem Yves,Vincenti Flavio,Reyes-Acevedo Rafael,Apanovitch Anne Marie,Gujrathi Sheila,Agarwal Mamta,Thomas Dolca,Larsen Christian P.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference24 articles.

1. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.;Larsen;Am J Transplant,2005

2. Hypertension in renal transplantation: Donor and recipient risk factors.;Ducloux;Clin Nephrol,2002

3. Drug-related dyslipidemia after renal transplantation.;Mathis;Am J Health Syst Pharm,2004

4. The natural history of chronic allograft nephropathy.;Nankivell;N Engl J Med,2003

5. Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation.;Roland;Transpl Int,2008

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunosuppression in Kidney Transplant Recipients: An Update for the General Nephrologist;Advances in Kidney Disease and Health;2024-09

2. Long-term Safety in Epstein–Barr Virus–Seropositive Kidney-only Transplant Recipients Treated With Belatacept in Clinical Practice: Final Study Results From the ENLiST Registry;Transplantation Direct;2024-05-17

3. Basics and Art of Immunosuppression in Liver Transplantation;Journal of Clinical and Experimental Hepatology;2024-05

4. Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis;Drug Safety;2024-02-07

5. Post-Transplant Lymphoproliferative Disorders;Seminars in Nephrology;2024-01